Minoxidil (Mx) as a prophylaxis of doxorubicin--induced alopecia.
3 Small study in people
How much this weighs: research in people, but small or without a comparison group.
- Type of study
- controlled trial
- Studied in
- people
- Participants
- not stated in the abstract
- Published
- 1995 in Annals of oncology : official journal of the European Society for Medical Oncology
- Cited
- 16 times by other research
- Who paid
- Not declared. PubMed carries no conflict-of-interest statement for most articles; that is not the same as independent.
- Source
- PubMed 7826913 · doi 10.1093/oxfordjournals.annonc.a058986
The plain-language write-up of this study is still being written.
Below is the abstract exactly as the researchers published it.
Abstract by the researchers — original text
BACKGROUND: Minoxidil (Mx) is known to induce hair growth in men with male-pattern baldness. Based on this potential, the effectiveness of Mx 2% topical solution was evaluated in cancer patients (pts) to prevent doxorubicin-induced alopecia. PATIENTS AND METHODS: 48 female pts with different types of solid tumors treated with doxorubicin-based chemotherapy in a dose range of 50-60 mg/m2/cycle were randomly assigned to receive Mx 2% topical solution or placebo. RESULTS: 88% and 92% of pts in both arms showed severe alopecia (p = ns). No adverse effects were observed. CONCLUSION: In this study Mx 2% topical solution was non-toxic but was not effective in the prevention of chemotherapy-induced alopecia.